Radium-223 Dichloride Long-term Follow-up Program

Official Title

A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride

Summary:

Patients will be followed up in this study after prior treatment with BAY 88-8223 / Radium-223 dichloride / Xofigo .

Trial Description

Primary Outcome Measures :

  • Incidence of radium-223 dichloride related Adverse Events
  • Severity of radium-223 dichloride related Adverse Events
  • Incidence of radium-223 dichloride related Serious Adverse Events
  • Incidence of placebo-related Adverse Events
  • Severity of placebo-related Adverse Events
  • Incidence of placebo-related Serious Adverse Events
  • Incidence of leukemia
  • Incidence of myelodysplastic syndrome
  • Incidence of aplastic anemia
  • Incidence of primary bone cancer [ Time Frame: Up to 7 years ]Incidence of any other new primary malignancy
  • Incidence of bone fractures
  • Incidence of bone-associated events
  • Incidence of febrile neutropenia in subjects who receive cytotoxic chemotherapy [ Time Frame: Up to 7 years

This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials).

The primary objectives are to define the long term safety profile of radium-223 dichloride (for up to 7 years after the last dose of radium-223 dichloride); to assess the incidence of leukemia, myelodysplastic syndrome, aplastic anemia, and primary bone cancer or any other new primary malignancy; to assess the incidence of bone fractures and bone associated events (e.g., osteoporosis); and, in subjects who receive cytotoxic chemotherapy, to assess the incidence of febrile neutropenia and hemorrhage during their chemotherapy treatment and for up to 6 months thereafter at a frequency based on local clinical practice.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society